John Doyle on clinical value
From John Doyle at Swiss Biotech · · Fortrea
“I think often we're hyper focused on clinical value, and obviously it makes perfect sense to start there but not end there. There are a lot of elements to value that biotech companies should consider to ensure that they're optimizing the value of their assets and their company.”
On , John Doyle, Chief Scientific Officer & President of Consulting Services at FORTREA HOLDINGS INC, spoke about clinical value during John Doyle at Swiss Biotech on Fortrea.
About John Doyle
At the Swiss Biotech conference on May 17, 2025, John Doyle, Chief Scientific Officer and President of Consulting at Fortrea Holdings, discussed value optimization for biotech companies. He argued that companies should think "holistically about value," moving beyond a focus on clinical value to consider patient or humanistic value, as well as economic value. Doyle noted that humanistic value can be measured through traditional methods like clinical outcome assessments and patient-reported outcomes, as well as emerging techniques using digital health technology and wearables that generate patient experience data passively. Doyle stated that economic value must be demonstrated with evidence, and that companies often need to translate clinical and humanistic value into economic terms to be measured and rewarded by payers and health technology assessment agencies. He observed that the industry is moving toward a "convergence of regulatory review as well as value appraisal," and that biotech companies can now focus on generating value for multiple stakeholders simultaneously.